


Curriculum Vitae

**CV must be written in English*

Personal Information



Title (i.e. Prof., Dr., etc.)	Prof.
Name (First / Middle / Last)	Taku Kobayashi
Degree (i.e. MD, MSc, PhD, etc.)	MD, PhD
Country	Japan
Affiliation	Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital

Educational Background

EDUCATION:

- 1992-1998 Nagoya University School of Medicine, Nagoya, Japan (M.D.)
 2004-2008 Nagoya University Graduate School of Medicine, Nagoya, Japan (Ph.D.)

INTERNSHIPS AND RESIDENCIES:

- 1998-2000 Residency in Medicine, Toyohashi Municipal Hospital, Aichi, Japan
 2000-2002 Residency in Internal Medicine, Toyohashi Municipal Hospital, Aichi, Japan

FELLOWSHIPS:

- 2002-2004 Clinical Fellowship in Internal Medicine, KKR Tokai Hospital, Nagoya
 2004-2008 Researcher in Gastroenterology, Keio University, Tokyo, Japan

Professional Experience

- 2008-2009 Instructor, Department of Gastroenterology, Keio University, Tokyo, Japan
 2009-2012 Postdoctoral Research Associate, University of North Carolina at Chapel Hill, NC, USA
 2012-2013 Chief Physician, Department of Gastroenterology, Kitasato University Kitasato Institute Hospital
 2013-2020 Visiting Associate Professor, Keio University, Tokyo, Japan
 2013-2022 Vice Director, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
 2022- present Director, Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital
 2022-present Associate Professor, Department of Gastroenterology, Kitasato University School of Medicine
 2024-present Assistant Director of Kitasato University Kitasato Institute Hospital
 2025 – Present Project Professor (Intestinal-Brain Interaction Therapy), Keio University School of Medicine
 2025 – Present Concurrent Faculty Appointment, Specially Appointed Associate Professor, Kitasato University Graduate School of Medical Sciences

Professional Organizations

- American Gastroenterological Association
 European Crohn's and Colitis Organization
 Japanese Society of Internal Medicine

Japanese Society of Gastroenterology
Japanese Society of Gastroenterological Endoscopy
Japan Society of Coloproctology
The Japan Society of Colon Examination
Japanese Society for Inflammatory Bowel Diseases
Asian Organization of Crohn's and Colitis
Japanese Society for Mucosal Immunology
Japanese Gastroenterological Association

Main Scientific Publications

1. Hrats L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinović A, Williamson T, Abbey Y, Abreu MT, Raja Ali RA, Abdullah M, Altuwajiri M, Ahuja V, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Geary R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones G-R, Juliao-Baños F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees C, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Ng KK, Okabayashi S, Olén O, Panaccione R, Paudel MS, Quaresma AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Vergara BI, Wei SC, Yamamoto-Furusho JK, Yang S-K, Ng SC, Kaplan GG; on behalf of the GIVES-21 Research Group. The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages. *Nature* (2025). doi.org/10.1038/s41586-025-08940-0
2. Adamina M, Minozzi S, Warusavitarne J, Buskens CJ, Chaparro M, Verstockt B, Kopylov U, Yanai H, Vavricka SR, Sigall-Boneh R, Sica GS, Reenaers C, Peros G, Papamichael K, Noor N, Moran GW, Maaser C, Luglio G, Kotze PG, Kobayashi T, Karmiris K, Kapizioni C, Iqbal N, Lacucci M, Holubar S, Hanzel J, Sabino JG, Gisbert JP, Fiorino G, Fidalgo C, Ellu P, El-Hussuna A, de Groof J, Czuber-dochan W, Casanova MJ, Burisch J, Brown SR, Bislenghi G, Bettenworth D, Battat R, Atreya R, Allocca M, Agrawal M, Raine T, Gordon H, Myreid P. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. *J Crohns Colitis*. 2024 Oct 15; 18(10): 1556-1582.
3. Gordon H, Minozzi S, Kopylov U, Verstockt B, Chaparro M, Buskens C, Warusavitarne J, Agrawal M, Allocca M, Atreya R, Battat R, Bettenworth D, Bislenghi G, Brown SR, Burisch J, Casanova MJ, Czuber-Dochan W, de Groof J, El-Hussuna A, Ellul P, Fidalgo C, Fiorino G, Gisbert JP, Sabino JG, Hanzel J, Holubar S, Iacucci M, Iqbal N, Kapizioni C, Karmiris K, Kobayashi T, Kotze PG, Luglio G, Maaser C, Moran G, Noor N, Papamichael K, Peros G, Reenaers C, Sica G, Sigall-Boneh R, Vavricka SR, Yanai H, Myreid P, Adamina M, Raine T. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *J Crohns Colitis*. 2024 Oct 15; 18(10): 1531-1555.
4. D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lisssoos T, Milata J, Morris N, Arora V, Milch C, Sandborn WJ, Sands BE, for the LUCENT Study Group. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med*. 2023 Jun 29. 388(26):2444-2455.
5. Kobayashi T and Hibi T. Improving IBD outcomes in the era of many treatment options. *Nat Rev Gastroenterol Hepatol*. 2022 Mar;20(3):195.
6. Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. *Aliment Pharmacol Ther* 2022;May;55(10):1320-1329.
7. Kobayashi T, Motoya S, Nakamura S, Yamamoto T, Nagahori M, Tanaka S, Hisamatsu T, Hirai F, Nakase H, Watanabe K, Matsumoto T, Tanaka M, Abe T, Suzuki Y, Watanabe M, Hibi T, on behalf of the HAYABUSA Study Group. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2021 Jun;6(6):429-437.
8. Sagami S, Kobayashi T, Miyatani Y, Okabayashi S, Yamazaki H, Kinoshita K, Allocca M, Kunisaki R, Ramaswamy PK, Shiraki M, Hibi T, Kataoka Y. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol*. 2021

AOCC 2026

IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA



May;19(5):908-921.

9. Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, and Hibi T. Ulcerative colitis. *Nature Rev Dis Primers*. 2020 Sep 10;6(1):74.
10. Sagami S, Kobayashi T, Aihara K, Umeda M, Morikubo H, Matsubayashi M, Kiyohara H, Nakano M, Ohbu M, Hibi T. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. *Aliment Pharmacol Ther*. 2020 51:1373-1383.
11. Sandborn WJ, Baert F, Danese S, Krznarić Z, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. *Gastroenterol*. 2020 Feb;158(3):562-572.
12. Ozaki R, Kobayashi T, Okabayashi S, Nakano M, Morinaga S, Hara A, Ohbu M, Matsuoka K, Toyonaga T, Saito E, Hisamatsu T, Hibi T. Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis with Endoscopically Normal Mucosa. *J Crohns Colitis*. 2018 Nov 15;12(11):1288-1294.
13. Matsuoka K, Kobayashi T* [first authorship shared], Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi K, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. *J Gastroenterol* 2018 Mar;53(3):305-353.
14. Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Osaki K, Watanabe M, Hibi T. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post-hoc analysis. *J Gastroenterol*. 2016 Mar;51(3):241-51
15. Kobayashi T, Steinbach EC, Russo SM, Matsuoka K, Nochi T, Maharshak N, Borst LB, Hostager B, Garcia-Martinez JV, Rothman PB, Kashiwada M, Sheikh SZ, Murray PJ, Plevy SE. NFIL3-Deficient Mice Develop Microbiota-Dependent, IL-12/23-Driven Spontaneous Colitis. *J Immunol*. 2014 Feb 15;192(4):1918-27.
16. Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T. IL-23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. *Gut*. 2008;57(12):1682-89.

>180 publications with >7000 citations